Suneva Medical, a US-based company producer of dermatological treatments, raised $35.4m in financing on Wednesday, including $15m in series C capital from pharmaceutical company Almirall.
In addition to the equity investment, Suneva secured $20.4m in debt from HealthCare Royalty Partners, which has been used partially to pay off an outstanding growth capital loan, and an undisclosed amount of working capital from Comerica Bank.
Suneva has developed a range of aesthetics products for dermatological conditions, and its lead product, Bellafill, treats facial scarring caused by acne.
The combined equity and debt financing will be used to support continued commercialisation efforts. Almirall will also take a seat on Suneva’s board of directors.
Suneva previously raised a $20m in series B funding in January 2014 from Polaris Partners and HealthCare Royalty Partners, and an additional $15m in debt from HealthCare Royalty and Comerica.
The company secured $35.2m in series A funding in 2012 and another $10m in 2013, according to regulatory filings.
Nicholas Teti Jr, chairman and chief executive of Suneva, said: “The Almirall equity investment will accelerate the growth for our current product portfolio and allow us the flexibility to continue to build one of the industry’s leading, fully integrated aesthetics companies.”